Biocon Biologics Ltd., a subsidiary of Biocon Ltd., entered into a definitive agreement to acquire Viatris’ biosimilars assets to create an integrated global biosimilars business. Viatris will receive consideration of as much as $3.3 billion, including cash up to $2.3 billion and Compulsorily Convertible Preference Shares (CCPS) in BBL, valued at $1 billion. The Board of Directors of both companies have approved the transaction.   BBL will have a portfolio comprising its current range of comme...